Popular diabetes drug shown to lower inflammation, which may protect the heart

Дата публикации: 06-10-2026 11:00:05

For the first time in a human trial, a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, already known for their weight-loss and glucose-lowering benefits, has also been shown to reduce inflammatory cells in the blood known to cause cardiovascular disease. The findings were published in Circulation.

Основное содержимое страницы с новостью.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Popular GLP-1 weight-loss drugs like Ozempic slash heart attack and stroke risk	0	9.67	21-05-2026
2	Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds	0	10.14	13-10-2026
3	Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity	7	8	31-07-2025
4	GLP-1s may improve outcomes in patients with PAD, diabetes	5	7	08-07-2026
5	This 10-cent heart drug cuts hospitalizations by 25%	0	16.47	16-08-2026
6	World Heart Day: San Diego heart surgeon breaks down GLP-1s, cholesterol and lowering surgical risk	0	6.07	29-09-2026
7	Semaglutide’s CV benefits may be related to more than weight loss	0	9.18	14-10-2026
8	After weight loss, exercise beats weight-loss drugs for heart health	0	9.66	21-07-2026
9	Commonly prescribed blood-pressure drug may stimulate 'healthy' brown fat	0	9.02	14-10-2026
10	Dying fat cells may trigger self-amplifying cycle of inflammation in obesity	0	9.47	07-10-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.73. Источник: medicalxpress.com.